Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans

Background: To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphine/naloxone (SL-BUP/NLX) are considered the standard of care for OUD including...

Full description

Bibliographic Details
Main Authors: Davis, C. (Author), Ferguson, R. (Author), Goldberg, A. (Author), Gordon, A.J (Author), Gu, L. (Author), Hermos, J. (Author), Kosten, T.R (Author), Lew, R. (Author), Nuite, M. (Author), Nunes, E.V (Author), Petrakis, I. (Author), Ralevski, E. (Author), Ringer, R. (Author), Rosenheck, R. (Author), Saxon, A.J (Author), Springer, S.A (Author), Swift, R. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
buprenorphine
Buprenorphine
Comparative effectiveness trial
controlled study
COVID-19
human
Humans
Injectable
narcotic antagonist
Narcotic Antagonists
opiate addiction
Opioid use disorder
Opioid-Related Disorders
randomized controlled trial
SARS-CoV-2
veteran
Veterans
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items